Comparative Pharmacology
Head-to-head clinical analysis: PANMYCIN versus TETRACHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANMYCIN versus TETRACHEL.
PANMYCIN vs TETRACHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A site.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
250-500 mg PO q6h or 500 mg to 1 g IV q6h; maximum 4 g/day
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function. Half-life is significantly prolonged (up to 80 hours) in anuria, requiring dose adjustment.
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Primarily renal excretion of unchanged drug via glomerular filtration; 80-90% recovered in urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic